

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761140Orig1s000

PROPRIETARY NAME REVIEW(S)

MEMORANDUM
NONPROPRIETARY NAME SUFFIX

Division of Medication Error Prevention and Analysis (DMEPA)
Office of Medication Error Prevention and Risk Management (OMEPRM) c
Office of Surveillance and Epidemiology (OSE) c
Center for Drug Evaluation and Research (CDER) c

*** This document contains proprietary information that cannot be released to the public*** c

Date of This Review:	May 28, 2020
Responsible OND Division:	Division of Hematologic Malignancies 2 (DHM2)
Application Type and Number:	BLA 761140
Product Name and Strength:	Riabni (rituximab-arrx) injection 100 mg/10 mL and 500 mg/50 mL (10 mg/mL)
Product Type:	Single Ingredient Product
Applicant/Sponsor Name:	Amgen Inc. (Amgen)
FDA Received Date:	December 19, 2019
OSE RCM #:	2019-2614
DMEPA Primary Reviewer:	Carlos M Mena-Grillasca, BS Pharm
DMEPA Deputy Director:	Danielle Harris, PharmD

1 PURPOSE OF MEMO

This memorandum is to reassess the suffix, -arrx, for BLA 761140, which was found conditionally acceptable under IND 118281 on July 10, 2019^a, for inclusion in the nonproprietary name and communicates our recommendation for the nonproprietary name for BLA 761140.

1.1 Regulatory History

FDA found the proposed suffix -arrx conditionally acceptable during the review of suffixes submitted to IND 118281^b.

On December 19, 2019 Amgen submitted BLA 761140 to the Agency for review.

2 ASSESSMENT OF THE NONPROPRIETARY NAME

rituximab-arrx

We reassessed the conditionally acceptable four-letter suffix, -arrx, using the principles described in the applicable guidance^c.

We determined that the suffix -arrx, is not too similar to any other products' suffix designation, does not look similar to the names of other currently marketed products, that the suffix is devoid of meaning, does not include any abbreviations that could be misinterpreted, and does not make any misrepresentations with respect to safety or efficacy of this product.

3 COMMUNICATION OF DMEPA'S ANALYSIS

These findings were shared with OPDP. In email correspondence dated May 27, 2020, OPDP did not identify any concerns that would render this suffix unacceptable. DMEPA also communicated our findings to the Division of Hematologic Malignancies 2 (DHM2) via e-mail on May 28, 2020.

^a Harris, D. General Advice Letter (IND 118281). Silver Spring (MD): FDA, CDER, OSE, DMEPA (US); 2019 Jul 10.

^b Mena-Grillasca, C. Nonproprietary Name Suffix Review for Riabni (IND 118281). Silver Spring (MD): FDA, CDER, OSE, DMEPA (US) 2019 Jun 13. RCM# 2018-2309

^c See Section VI which describes that any suffixes should be devoid of meaning in Guidance for Industry: Nonproprietary Naming of Biological Products. 2017. Available from:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.pdf>

4 CONCLUSION

We find the proposed suffix -arrx acceptable. DMEPA will communicate our findings to the Applicant via letter.

4.1 Recommendations for Amgen Inc.

We find the nonproprietary name, rituximab-arrx, conditionally acceptable for your proposed product. Should your 351(k) BLA be approved during this review cycle, rituximab-arrx will be the proper name designated in the license. However, please be advised that if your application receives a complete response, the acceptability of your proposed suffix will be re-evaluated when you respond to the deficiencies. If we find your suffix unacceptable upon our re-evaluation, we would inform you of our finding.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

CARLOS M MENA-GRILLASCA
05/28/2020 06:02:05 PM

DANIELLE M HARRIS
05/29/2020 08:41:18 AM

PROPRIETARY NAME REVIEW

Division of Medication Error Prevention and Analysis (DMEPA)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

***** This document contains proprietary information that cannot be released to the public*****

Date of This Review:	March 2, 2020
Application Type and Number:	BLA 761140
Product Name and Strength:	Riabni (rituximab-xxxx)* injection 100 mg/10 mL (10 mg/mL) 500 mg/50 mL (10 mg/mL)
Total Product Strength:	100 mg/10 mL and 500 mg/50 mL
Product Type:	Single Ingredient Product
Rx or OTC:	Prescription (Rx)
Applicant/Sponsor Name:	Amgen
Panorama #:	2019-36605780
DMEPA Safety Evaluator:	Stephanie DeGraw, PharmD
DMEPA Team Leader:	Hina Mehta, PharmD

* The nonproprietary name suffix for this BLA has not yet been determined; therefore, the placeholder, rituximab-xxxx, is used throughout this review to refer to the nonproprietary name and suffix for this product.

Contents

1	INTRODUCTION	1
1.1	Regulatory History.....	1
1.2	Product Information.....	1
2	RESULTS.....	2
2.1	Misbranding Assessment.....	2
2.2	Safety Assessment	2
3	CONCLUSION	4
3.1	Comments to Amgen	4
4	REFERENCES	5
	APPENDICES	6

1 INTRODUCTION

This review evaluates the proposed proprietary name, Riabni, from a safety and misbranding perspective. The sources and methods used to evaluate the proposed proprietary name are outlined in the reference section and Appendix A respectively. Amgen did not submit an external name study for this proposed proprietary name.

1.1 REGULATORY HISTORY

The Applicant submitted the name, Riabni, for review on July 18, 2018 under IND 118281. DMEPA found the name to be acceptable on January 7, 2019.^a Amgen resubmitted the name, Riabni, for review under the BLA on December 19, 2019.

1.2 PRODUCT INFORMATION

The following product information is provided in the proprietary name submission received on December 19, 2019.

- Intended Pronunciation: ree-AB-nee
- Active Ingredient: rituximab-xxxx
- Indication of Use: Treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA) in combination with methotrexate in adult patients with moderately to severely active RA who have inadequate response to one or more TNF antagonist therapies, granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA) in adult patients in combination with glucocorticoids.
- Route of Administration: Intravenous infusion
- Dosage Form: injection
- Strength: 100 mg/10 mL (10 mg/mL) and 500 mg/50 mL (10 mg/mL)
- Dose and Frequency:
 - The dose for NHL is 375 mg/m²
 - The dose for CLL is 375 mg/m² in the first cycle and 500 mg/m² in cycles 2-6, in combination with FC, administered every 28 days
 - The dose as a component of Zevalin[®] (ibritumomab tiuxetan) Therapeutic Regimen is 250 mg/m²
 -  (b) (4)

^a Ogbonna, C. Proprietary Name Review for Riabni (IND 118281). Silver Spring (MD): FDA, CDER, OSE, DMEPA (US); 2019 JAN 7. Panorama No. 2018-24634834.

- The induction dose for adult patients with active GPA and MPA in combination with glucocorticoids is 375 mg/m² once weekly for 4 weeks. The follow up dose for adult patients with GPA and MPA who have achieved disease control with induction treatment, in combination with glucocorticoids is two 500 mg intravenous infusions separated by two weeks, followed by a 500 mg intravenous infusion every 6 months thereafter based on clinical evaluation
- How Supplied: RIABNI injection is a sterile, preservative-free clear to slightly opalescent, colorless to slightly yellow solution for intravenous infusion supplied as single-dose vials of 100 mg/10 mL (10 mg/mL) in cartons of one vial (NDC 55513-224-01) and single-dose vials of 500 mg/50 mL (10 mg/mL) in a carton of one vial (NDC 55513-326-01).
- Storage: Refrigerated at 2°C to 8°C (36°F to 46°F). Protect from direct sunlight. Do not freeze or shake.
- Reference Listed Drug/Reference Product: Rituxan BLA 103705

2 RESULTS

The following sections provide information obtained and considered in the overall evaluation of the proposed proprietary name, Riabni.

2.1 MISBRANDING ASSESSMENT

The Office of Prescription Drug Promotion (OPDP) determined that Riabni would not misbrand the proposed product. The Division of Medication Error Prevention and Analysis (DMEPA) and the Division of Hematology Products (DHP) concurred with the findings of OPDP's assessment for Riabni.

2.2 SAFETY ASSESSMENT

The following aspects were considered in the safety evaluation of the proposed proprietary name, Riabni.

2.2.1 *United States Adopted Names (USAN) Search*

There is no USAN stem present in the proposed proprietary name^b.

2.2.2 *Components of the Proposed Proprietary Name*

Amgen did not provide a derivation or intended meaning for the proposed proprietary name, Riabni, in their submission. The proprietary name is comprised of a single word that does not contain any components (i.e. a modifier, route of administration, dosage form, etc.) that are misleading or can contribute to medication error.

2.2.3 *Comments from Other Review Disciplines at Initial Review*

In response to the OSE, January 13, 2020 e-mail, the Division of Hematology Products (DHP) did not forward any comments or concerns relating to Riabni at the initial phase of the review.

^b USAN stem search conducted on January 22, 2020.

2.2.4 FDA Name Simulation Studies

Ninety-eight (98) practitioners participated in DMEPA's prescription studies for Riabni. The responses did not overlap with any currently marketed products nor did the responses sound or look similar to any currently marketed products or any products in the pipeline. Appendix B contains the results from the studies.

2.2.5 Phonetic and Orthographic Computer Analysis (POCA) Search Results

Our POCA search^c identified 111 names with the combined score of $\geq 55\%$ or individual orthographic or phonetic score of $\geq 70\%$. We had identified and evaluated some of the names in our previous proprietary name review. We re-evaluated the previously identified names of concern considering any lessons learned from recent post-marketing experience, which may have altered our previous conclusion regarding the acceptability of the name. We note that none of the product characteristics have changed and we agree with the findings from our previous review for the names evaluated previously. Therefore, we identified four (4) names not previously analyzed. These names are included in Table 1 below.

2.2.6 Names Retrieved for Review Organized by Name Pair Similarity

Table 1 lists the number of names retrieved from our POCA search. These name pairs are organized as highly similar, moderately similar or low similarity for further evaluation.

Table 1. Names Retrieved for Review Organized by Name Pair Similarity	
Similarity Category	Number of Names
Highly similar name pair: combined match percentage score $\geq 70\%$	0
Moderately similar name pair: combined match percentage score $\geq 55\%$ to $\leq 69\%$	4
Low similarity name pair: combined match percentage score $\leq 54\%$	0

2.2.7 Safety Analysis of Names with Potential Orthographic, Spelling, and Phonetic Similarities

Our analysis of the four (4) names contained in Table 1 determined none of the names will pose a risk for confusion with Riabni as described in Appendices C through H.

2.2.8 Communication of DMEPA's Analysis at Midpoint of Review

DMEPA communicated our findings to the Division of Hematology Products (DHP) via e-mail on February 24, 2020. At that time, we also requested additional information or concerns that could inform our review. Per e-mail correspondence from the Division of Hematology Products (DHP) on March 2, 2020, they stated no additional concerns with the proposed proprietary name, Riabni.

^c POCA search conducted on January 22, 2020 in version 4.3.

3 CONCLUSION

The proposed proprietary name, Riabni, is acceptable.

If you have any questions or need clarifications, please contact Neil Vora, OSE project manager, at 240-402-4845.

3.1 COMMENTS TO AMGEN

We have completed our review of the proposed proprietary name, Riabni, and have concluded that this name is acceptable.

If any of the proposed product characteristics as stated in your submission, received on December 19, 2019, are altered prior to approval of the marketing application, the name must be resubmitted for review.

4 REFERENCES

1. USAN Stems (<https://www.ama-assn.org/about/united-states-adopted-names-approved-stems>)

USAN Stems List contains all the recognized USAN stems.

2. *Phonetic and Orthographic Computer Analysis (POCA)*

POCA is a system that FDA designed. As part of the name similarity assessment, POCA is used to evaluate proposed names via a phonetic and orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists that operates in a similar fashion. POCA is publicly accessible.

Drugs@FDA

Drugs@FDA is an FDA Web site that contains most of the drug products approved in the United States since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA-approved *brand name* and *generic drugs*; *therapeutic biological products*, *prescription* and *over-the-counter* human drugs; and *discontinued drugs* (see Drugs @ FDA Glossary of Terms, available at http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm#ther_biological).

RxNorm

RxNorm contains the names of prescription and many OTC drugs available in the United States. RxNorm includes generic and branded:

- Clinical drugs – pharmaceutical products given to (or taken by) a patient with therapeutic or diagnostic intent
- Drug packs – packs that contain multiple drugs, or drugs designed to be administered in a specified sequence

Radiopharmaceuticals, contrast media, food, dietary supplements, and medical devices, such as bandages and crutches, are all out of scope for RxNorm (<http://www.nlm.nih.gov/research/umls/rxnorm/overview.html#>).

Division of Medication Errors Prevention and Analysis proprietary name consultation requests

This is a list of proposed and pending names that is generated by the Division of Medication Error Prevention and Analysis from the Access database/tracking system.

APPENDICES

Appendix A

FDA's Proprietary Name Risk Assessment evaluates proposed proprietary names for misbranding and safety concerns.

1. **Misbranding Assessment:** For prescription drug products, OPDP assesses the name for misbranding concerns. For over-the-counter (OTC) drug products, the misbranding assessment of the proposed name is conducted by DNDP. OPDP or DNDP evaluates proposed proprietary names to determine if the name is false or misleading, such as by making misrepresentations with respect to safety or efficacy. For example, a fanciful proprietary name may misbrand a product by suggesting that it has some unique effectiveness or composition when it does not (21 CFR 201.10(c)(3)). OPDP or DNDP provides their opinion to DMEPA for consideration in the overall acceptability of the proposed proprietary name.
2. **Safety Assessment:** The safety assessment is conducted by DMEPA, and includes the following:
 - a. **Preliminary Assessment:** We consider inclusion of USAN stems or other characteristics that when incorporated into a proprietary name may cause or contribute to medication errors (i.e., dosing interval, dosage form/route of administration, medical or product name abbreviations, names that include or suggest the composition of the drug product, etc.) See prescreening checklist below in Table 2*. DMEPA defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. ^d

^d National Coordinating Council for Medication Error Reporting and Prevention.
<http://www.nccmerp.org/aboutMedErrors.html>. Last accessed 10/11/2007.

***Table 2- Prescreening Checklist for Proposed Proprietary Name**

	Answer the questions in the checklist below. Affirmative answers to any of these questions indicate a potential area of concern that should be carefully evaluated as described in this guidance.
Y/N	Is the proposed name obviously similar in spelling and pronunciation to other names?
	Proprietary names should not be similar in spelling or pronunciation to proprietary names, established names, or ingredients of other products.
Y/N	Are there inert or inactive ingredients referenced in the proprietary name?
	Proprietary names should not incorporate any reference to an inert or inactive ingredient in a way that might create an impression that the ingredient's value is greater than its true functional role in the formulation (21 CFR 201.10(c)(4)).
Y/N	Does the proprietary name include combinations of active ingredients?
	Proprietary names of fixed combination drug products should not include or suggest the name of one or more, but not all, of its active ingredients (see 21 CFR 201.6(b)).
Y/N	Is there a United States Adopted Name (USAN) stem in the proprietary name?
	Proprietary names should not incorporate a USAN stem in the position that USAN designates for the stem.
Y/N	Is this proprietary name used for another product that does not share at least one common active ingredient?
	Drug products that do not contain at least one common active ingredient should not use the same (root) proprietary name.
Y/N	Is this a proprietary name of a discontinued product?
	Proprietary names should not use the proprietary name of a discontinued product if that discontinued drug product does not contain the same active ingredients.

- b. Phonetic and Orthographic Computer Analysis (POCA): Following the preliminary screening of the proposed proprietary name, DMEPA staff evaluates the proposed name against potentially similar names. In order to identify names with potential similarity to the proposed proprietary name, DMEPA enters the proposed proprietary name in POCA and queries the name against the following drug reference databases, Drugs@fda, CernerRxNorm, and names in the review pipeline using a 55% threshold in POCA. DMEPA reviews the combined orthographic and phonetic matches and group the names into one of the following three categories:
- Highly similar pair: combined match percentage score $\geq 70\%$.
 - Moderately similar pair: combined match percentage score $\geq 55\%$ to $\leq 69\%$.
 - Low similarity: combined match percentage score $\leq 54\%$.

Using the criteria outlined in the check list (Table 3-5) that corresponds to each of the three categories (highly similar pair, moderately similar pair, and low similarity), DMEPA evaluates the name pairs to determine the acceptability or non-acceptability of a proposed proprietary name. The intent of these checklists is to increase the transparency and predictability of the safety determination of whether a proposed name is vulnerable to confusion from a look-alike or sound-alike perspective. Each bullet below corresponds to the name similarity category cross-references the respective table that addresses criteria that DMEPA uses to determine whether a name presents a safety concern from a look-alike or sound-alike perspective.

- For highly similar names, differences in product characteristics often cannot mitigate the risk of a medication error, including product differences such as strength and dose. Thus, proposed proprietary names that have a combined score of ≥ 70 percent are at risk for a look-alike sound-alike confusion which is an area of concern (See Table 3).
- Moderately similar names are further evaluated to identify the presence of attributes that are known to cause name confusion.
 - Name attributes: We note that the beginning of the drug name plays a significant role in contributing to confusion. Additionally, drug name pairs that start with the same first letter and contain a shared letter string of at least 3 letters in both names are major contributing factor in the confusion of drug names^c. We evaluate all moderately similar names retrieved from POCA to identify the above attributes. These names are further evaluated to identify overlapping or similar strengths or doses.
 - Product attributes: Moderately similar names of products that have overlapping or similar strengths or doses represent an area for concern for FDA. The dose and strength information is often located in close proximity to the drug name itself on prescriptions and medication orders, and the information can be an important factor that either increases or decreases the potential for confusion between similarly named drug pairs. The ability of other product characteristics to mitigate confusion (e.g., route, frequency, dosage form) may be limited when the strength or dose overlaps. DMEPA reviews such names further, to determine whether sufficient differences exist to prevent confusion. (See Table 4).
- Names with low similarity that have no overlap or similarity in strength and dose are generally acceptable (See Table 5) unless there are data to suggest that the name might be vulnerable to confusion (e.g., prescription simulation study suggests that the name is likely to be misinterpreted as a marketed product). In these instances, we would reassign a low similarity name to the moderate similarity category and review according to the moderately similar name pair checklist.

^c Shah, M, Merchant, L, Characteristics That May Help in the Identification of Potentially Confusing Proprietary Drug Names. Therapeutic Innovation & Regulatory Science, September 2016

- c. FDA Prescription Simulation Studies: DMEPA staff also conducts a prescription simulation studies using FDA health care professionals.

Four separate studies are conducted within the Centers of the FDA for the proposed proprietary name to determine the degree of confusion of the proposed proprietary name with marketed U.S. drug names (proprietary and established) due to similarity in visual appearance with handwritten prescriptions, verbal pronunciation of the drug name or during computerized provider order entry. The studies employ healthcare professionals (pharmacists, physicians, and nurses), and attempts to simulate the prescription ordering process. The primary Safety Evaluator uses the results to identify vulnerability of the proposed name to be misinterpreted by healthcare practitioners during written, verbal, or electronic prescribing.

In order to evaluate the potential for misinterpretation of the proposed proprietary name during written, verbal, or electronic prescribing of the name, written inpatient medication orders, written outpatient prescriptions, verbal orders, and electronic orders are simulated, each consisting of a combination of marketed and unapproved drug products, including the proposed name.

- d. Comments from Other Review Disciplines: DMEPA requests the Office of New Drugs (OND) and/or Office of Generic Drugs (OGD), ONDQA or OBP for their comments or concerns with the proposed proprietary name, ask for any clinical issues that may impact the DMEPA review during the initial phase of the name review. Additionally, when applicable, at the same time DMEPA requests concurrence/non-concurrence with OPDP's decision on the name. The primary Safety Evaluator addresses any comments or concerns in the safety evaluator's assessment.

The OND/OGD Regulatory Division is contacted a second time following our analysis of the proposed proprietary name. At this point, DMEPA conveys their decision to accept or reject the name. The OND or OGD Regulatory Division is requested to provide any further information that might inform DMEPA's final decision on the proposed name.

Additionally, other review disciplines opinions such as ONDQA or OBP may be considered depending on the proposed proprietary name.

When provided, DMEPA considers external proprietary name studies conducted by or for the Applicant/Sponsor and incorporates the findings of these studies into the overall risk assessment.

The DMEPA primary reviewer assigned to evaluate the proposed proprietary name is responsible for considering the collective findings and provides an overall risk assessment of the proposed proprietary name.

Table 3. Highly Similar Name Pair Checklist (i.e., combined Orthographic and Phonetic score is $\geq 70\%$).

Answer the questions in the checklist below. Affirmative answers to some of these questions suggest that the pattern of orthographic or phonetic differences in the names may render the names less likely to confusion, provided that the pair does not share a common strength or dose.			
<u>Orthographic Checklist</u>		<u>Phonetic Checklist</u>	
Y/N	Do the names begin with different first letters? <i>Note that even when names begin with different first letters, certain letters may be confused with each other when scripted.</i>	Y/N	Do the names have different number of syllables?
Y/N	Are the lengths of the names dissimilar* when scripted? <i>*FDA considers the length of names different if the names differ by two or more letters.</i>	Y/N	Do the names have different syllabic stresses?
Y/N	Considering variations in scripting of some letters (such as z and f), is there a different number or placement of upstroke/downstroke letters present in the names?	Y/N	Do the syllables have different phonologic processes, such vowel reduction, assimilation, or deletion?
Y/N	Is there different number or placement of cross-stroke or dotted letters present in the names?	Y/N	Across a range of dialects, are the names consistently pronounced differently?
Y/N	Do the infixes of the name appear dissimilar when scripted?		
Y/N	Do the suffixes of the names appear dissimilar when scripted?		

Table 4: Moderately Similar Name Pair Checklist (i.e., combined score is $\geq 55\%$ to $\leq 69\%$).

Step 1	Review the DOSAGE AND ADMINISTRATION and HOW SUPPLIED/STORAGE AND HANDLING sections of the prescribing information (or for OTC drugs refer to the Drug Facts label) to determine if strengths and doses of the name pair overlap or are very similar. Different strengths and doses for products whose names are moderately similar may decrease the risk of confusion between the moderately similar name pairs. Name pairs that have overlapping or similar strengths or doses have a higher potential for confusion and should be evaluated further (see Step 2). Because the strength or dose could be used to express an order or prescription for a particular drug product, overlap in one or both of these components would be reason for further evaluation. For single strength products, also consider circumstances where the strength may not be expressed. For any i.e. drug products comprised of more than one active ingredient, consider whether the strength or dose may be expressed using only one of the components. To determine whether the strengths or doses are similar to your proposed product, consider the following list of factors that may increase confusion: • Alternative expressions of dose: 5 mL may be listed in the prescribing information, but the dose may be expressed in metric weight (e.g., 500 mg) or in non-metric units (e.g., 1 tsp, 1 tablet/capsule). Similarly, a strength or dose of 1000 mg may be expressed, in practice, as 1 g, or vice versa. • Trailing or deleting zeros: 10 mg is similar in appearance to 100 mg which may potentiate confusion between a name pair with moderate similarity. • Similar sounding doses: 15 mg is similar in sound to 50 mg
Step 2	Answer the questions in the checklist below. Affirmative answers to some of these questions suggest that the pattern of orthographic or phonetic differences in the names may reduce the likelihood of confusion for moderately similar names <u>with</u> overlapping or similar strengths or doses.



Orthographic Checklist (Y/N to each question) - Do the names begin with different first letters? Note that even when names begin with different first letters, certain letters may be confused with each other when scripted. - Are the lengths of the names dissimilar* when scripted? *FDA considers the length of names different if the names differ by two or more letters. - Considering variations in scripting of some letters (such as z and f), is there a different number or placement of upstroke/downstroke letters present in the names? - Is there different number or placement of cross-stroke or dotted letters present in the names? - Do the infixes of the name appear dissimilar when scripted? - Do the suffixes of the names appear dissimilar when scripted?	Phonetic Checklist (Y/N to each question) - Do the names have different number of syllables? - Do the names have different syllabic stresses? - Do the syllables have different phonologic processes, such vowel reduction, assimilation, or deletion? - Across a range of dialects, are the names consistently pronounced differently?
--	---

Table 5: Low Similarity Name Pair Checklist (i.e., combined score is $\leq 54\%$).

Names with low similarity are generally acceptable unless there are data to suggest that the name might be vulnerable to confusion (e.g., prescription simulation study suggests that the name is likely to be misinterpreted as a marketed product). In these instances, we would reassign a low similarity name to the moderate similarity category and review according to the moderately similar name pair checklist.

Appendix B: Prescription Simulation Samples and Results

Figure 1. Riabni Study (Conducted on January 31, 2020)

Handwritten Medication Order/Prescription	Verbal Prescription
<u>Medication Order:</u> 	Riabni 500 mg Bring to clinic Dispense 2 vials
<u>Outpatient Prescription:</u> 	
CPOE Study Sample (displayed as sans-serif, 12-point, bold font)	
Riabni	

FDA Prescription Simulation Responses (Aggregate Report)

As of Date 2/12/2020

212 People Received Study
98 People Responded
Study Name: Riabni

Total	19	40	19	20	
INTERPRETATION	OUTPATIENT	CPOE	VOICE	INPATIENT	TOTAL
REABKNEE	0	0	1	0	1
REABNE	0	0	2	0	2
REABNEE	0	0	2	0	2
REABNEY	0	0	1	0	1
REABNI	0	0	8	0	8
REABNY	0	0	2	0	2
REAPNI	0	0	1	0	1
REAPNY	0	0	1	0	1
REHAPNE	0	0	1	0	1
RIABNE	0	0	0	1	1
RIABNI	4	40	0	14	58
RIABONE	0	0	0	1	1

RIABRI	15	0	0	0	15
RIALINE	0	0	0	1	1
RIOBINI	0	0	0	1	1
RIOBNI	0	0	0	1	1
RIOLBNIE	0	0	0	1	1

Appendix C: Highly Similar Names (e.g., combined POCA score is $\geq 70\%$) --- N/A

Appendix D: Moderately Similar Names (e.g., combined POCA score is $\geq 55\%$ to $\leq 69\%$) with no overlap or numerical similarity in Strength and/or Dose

No.	Name	POCA Score (%)
1.	(b) (4)***	60

Appendix E: Moderately Similar Names (e.g., combined POCA score is $\geq 55\%$ to $\leq 69\%$) with overlap or numerical similarity in Strength and/or Dose

No.	Proposed name: Riabni Established name: rituximab-xxxx Dosage form: injection Strength(s): 100 mg/10 mL and 500 mg/50 mL (both 20 mg/mL) Usual Dose: 250 mg/m ² or 375 mg/m ² or 500 mg/m ² or 500 mg or 1,000 mg	POCA Score (%)	Prevention of Failure Mode In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names
2.	Cerianna***	56	This name pair has sufficient orthographic and phonetic differences.

Appendix F: Low Similarity Names (e.g., combined POCA score is $\leq 54\%$) --- N/A

Appendix G: Names not likely to be confused or not used in usual practice settings for the reasons described.

No.	Name	POCA Score (%)	Failure preventions
3.	(b) (4)***	65	Proposed proprietary name for IND 115528 found unacceptable by DMEPA (b) (4) on 9/16/19. Proposed proprietary name Oriahnn*** was submitted and found conditionally acceptable by DMEPA under NDA 213388 (OSE 2019-035421863) on 12/26/19.

Appendix H: Names not likely to be confused due to absence of attributes that are known to cause name confusion^f.

No.	Name	POCA Score (%)
4.	(b) (4)***	56

^f Shah, M, Merchant, L, Chan, I, and Taylor, K. Characteristics That May Help in the Identification of Potentially Confusing Proprietary Drug Names. Therapeutic Innovation & Regulatory Science, September 2016

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

STEPHANIE L DEGRAW
03/02/2020 12:07:39 PM

HINA S MEHTA
03/02/2020 12:27:58 PM